Chemotherapy for recurrent/metastatic head and neck cancers

Karabajakian, Andy; Toussaint, Philippe; Neidhardt, Ève-Marie; Paulus, V.; Saintigny, Pierre; Fayette, Jérôme

doi:10.1097/cad.0000000000000473

Cited by 19 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, CTX has shown limited efficacy in HNSCC with an overall response rate of 10%–20%, contrasting with the high rates of EGFR overexpression ( 51 , 72 ). This underlines the existence of resistance mechanisms, remaining unresolved, but for which several hypotheses have been proposed ( 48 , 56 , 64 , 67 , 73 – 81 ) ( 4 , 12 , 21 , 24 , 29 – 37 ). The different type of resistance mechanisms to CTX could be defined as follows: alterations of the EGFR-ligand binding, alterations of the EGFR downstream signaling effectors, parallel/bypass pathway activation, alterations of proteins involved in classic cancer pathways, EMT, epigenetic alterations and establishment of an immunosuppressive TME ( Figure 1 ).…”

Section: Mechanisms Of Resistance To Cetuximabmentioning

confidence: 96%

“…More than half of HNSCC patients experience locoregional or distant relapse despite aggressive multimodal therapeutic approaches that include surgical resection (often with neck dissection), radiation therapy (exclusive or postoperative), and adjuvant chemotherapy given as a radiosensitizer ( 4 ). After relapse, treatment options are often limited due to a high risk of complications (e.g., fistulas, dysphagia, spinal cord myelopathy) if surgery or reirradiation are attempted.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers

et al. 2021

Self Cite

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer worldwide. More than half of HNSCC patients experience locoregional or distant relapse to treatment despite aggressive multimodal therapeutic approaches that include surgical resection, radiation therapy, and adjuvant chemotherapy. Before the arrival of immunotherapy, systemic chemotherapy was previously employed as the standard first-line protocol with an association of cisplatin or carboplatin plus 5-fluorouracil plus cetuximab (anti-EFGR antibody). Unfortunately, acquisition of therapy resistance is common in patients with HNSCC and often results in local and distant failure. Despite our better understanding of HNSCC biology, no other molecular-targeted agent has been approved for HNSCC. In this review, we outline the mechanisms of resistance to the therapeutic strategies currently used in HNSCC, discuss combination treatment strategies to overcome them, and summarize the therapeutic regimens that are presently being evaluated in early- and late-phase clinical trials.

show abstract

Section: Mechanisms Of Resistance To Cetuximabmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The literature shows that cytotoxic chemotherapy at both standard doses and low doses is associated with severe toxicities and fatalities . Although cytotoxic chemotherapy is the treatment option for most patients presenting with a recurrent/metastatic HNSCC, it use in patients with FA is discouraged.…”

Section: Treatment Of Oscc In Famentioning

confidence: 99%

Two enemies, one fight: An update of oral cancer in patients with Fanconi anemia

Amenábar

Torres‐Pereira

Tang

et al. 2019

Cancer

View full text Add to dashboard Cite

Fanconi anemia (FA) is a rare inherited genetic condition that may lead to bone marrow failure, leukemia, and/or solid tumors. It is caused by the loss of function of at least 1 gene of the FA/BRCA pathway, which is necessary for DNA repair. Patients with FA have a 200‐fold to 1000‐fold risk of developing head and neck cancer, mainly oral squamous cell carcinoma (OSCC), and of doing so at a much younger age than individuals within the general population. Also, patients who have FA with OSCC have poor overall survival rates, reinforcing the necessity to detect OSCC early. The scope of the current review is to provide an update on OSCC in patients with FA.

show abstract

“…Searching for such distinctive features in all types of HNSCC brings us closer to the creation of precision medicine solutions that will become alternative for the standard therapy consisting of chemo-and radiotherapy, surgical intervention, or systemic treatment, e.g., cisplatin, carboplatin, and cetuximab [14][15][16]. The main reason behind seeking personal medicine approaches is that more than 50% of the cases relapse despite administering aggressive multimodal therapy [17]. After that, high risk of complications significantly narrows down options for further treatment.…”

Section: Introductionmentioning

confidence: 99%

Long Intergenic Non-Coding RNAs in HNSCC: From “Junk DNA” to Important Prognostic Factor

Kozłowska

Kolenda

Poter

et al. 2021

Cancers

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma is one of the most common and fatal cancers worldwide. Even a multimodal approach consisting of standard chemo- and radiotherapy along with surgical resection is only effective in approximately 50% of the cases. The rest of the patients develop a relapse of the disease and acquire resistance to treatment. Especially this group of individuals needs novel, personalized, targeted therapy. The first step to discovering such solutions is to investigate the tumor microenvironment, thus understanding the role and mechanism of the function of coding and non-coding sequences of the human genome. In recent years, RNA molecules gained great interest when the complex character of their impact on our biology allowed them to come out of the shadows of the “junk DNA” label. Furthermore, long non-coding RNAs (lncRNA), specifically the intergenic subgroup (lincRNA), are one of the most aberrantly expressed in several malignancies, which makes them particularly promising future diagnostic biomarkers and therapeutic targets. This review contains characteristics of known and validated lincRNAs in HNSCC, such as XIST, MALAT, HOTAIR, HOTTIP, lincRNA-p21, LINC02487, LINC02195, LINC00668, LINC00519, LINC00511, LINC00460, LINC00312, and LINC00052, with a description of their prognostic abilities. Even though much work remains to be done, lincRNAs are important factors in cancer biology that will become valuable biomarkers of tumor stage, outcome prognosis, and contribution to personalized medicine.

show abstract

Chemotherapy for recurrent/metastatic head and neck cancers

Cited by 19 publications

References 25 publications

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers

Two enemies, one fight: An update of oral cancer in patients with Fanconi anemia

Long Intergenic Non-Coding RNAs in HNSCC: From “Junk DNA” to Important Prognostic Factor

Contact Info

Product

Resources

About